Heart Failure
Conditions
Keywords
child
Brief summary
This study aims at exploring the use of Dapagliflozin and Empagliflozin in children and adolescents 6-18 years old with heart failure. These molecules are effective in reducing hospitalisations and mortality in adults with heart failure and are used in adolescents with type 2 diabetes mellitus, but little is known on children with heart failure. Particularly, the best dose to use in this population is currently unknown. This trial aims to: 1. define a dose rationale for this indication and age group (pharmacokinetic study), 2. assess and monitor safety, 3. assess ease-of-swallow, 4. explore middle-term (4-6 weeks) efficacy and efficacy markers. Participants will be asked to attend 4 study visits over 4-6 weeks, and one end-study visit 2-12 weeks thereafter. Visits 1 and 3 will entail an 8h day-hospital stay, while Visits 2, 4 and the end-study visit will be outpatient clinics (approximately 2h). Participants will be asked to take the studied drug once daily during the 4-6 weeks of the study period. All participants will take both Dapagliflozin and Empagliflozin: 6 will start with Dapagliflozin first (Visits 1-2) and then switch to Empagliflozin (Visits 3-4), while 6 will start with Empagliflozin first (Visits 1-2) and then switch to Dapagliflozin (Visits 3-4). No comparison group is foreseen for this study.
Detailed description
Paediatric heart failure is a relevant healthcare issue, with almost 15'000 yearly hospitalizations just in the USA. Sadly, current heart failure therapy in Paediatrics is still unsatisfactory, with high in-hospital (7-26%), and 5-year mortality (30%-50%). Among the recent improvements in adult heart failure management, impressive is the discovery that Dapagliflozin and Empagliflozin are able to reduce cardiovascular death or worsening heart failure by 25% on top of optimal medical therapy. Indeed, since 2021, they have been recommended as part of standard heart failure therapy. In the past, paediatric heart failure trials often failed, mainly because of suboptimal dose or inappropriate formulations and endpoints. This phase II.a, cross-over, open-label trial is designed to characterize pharmacokinetics (primary outcome), palatability, safety and explore potential efficacy markers (secondary outcomes) of Dapagliflozin and Empagliflozin in 12 heart failure children, so to inform the design and performance of subsequent, state-of-the-art, high-quality efficacy trials. Participants will first receive Drug A (either Dapagliflozin, n=6, or Empagliflozin, n=6) during 3-5 weeks, followed by the other molecule (Drug B) for 2 weeks. They will have 4 visits, one end-study visit and 11-15 pharmacokinetic samples (depending on their weight). The timing of these samples will be optimized exploiting contemporary modeling and simulation techniques. Safety evaluation will occur throughout the study, while palatability will be evaluated at Visits 1 (Drug A) and 3 (Dug B), and efficacy markers at Visits 1, 3 and 4. Pharmacokinetic modeling will characterize primary and secondary pharmacokinetic parameters and allow to define the optimal paediatric dose, informing both current compassionate-care use and the design of future efficacy trials.
Interventions
Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3. Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4. Dose: * participants ≤12 year old: 5mg once daily p.o. (commercially available tablet) * participants \>12 year old: 10mg once daily p.o. (commercially available tablet)
Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3. Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4. Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)
Sponsors
Great Ormond Street Hospital for Children NHS Foundation Trust
University College, London
Centre Hospitalier Universitaire Vaudois
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Order of drug intake will be balanced and randomized, with 6 patients starting with Dapagliflozin (Visits 1-2) and subsequently switching to Empagliflozin (Visits 3-4), and 6 patients starting with Empagliflozin (Visits 1-2) and subsequently switching to Dapagliflozin (Visits 3-4).
Eligibility
Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children 6 to 18 years of age, followed either as in- or outpatients at the Heart failure unit, Great Ormond Street Hospital NHS Foundation Trust, London or at the Paediatric Cardiology Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University Hospital, Lausanne, Switzerland will be eligible for inclusion. * Currently on heart failure medication (any drug or any combination). * Patients should potentially benefit from adding a SGLT2i (as judged by the treating physician and the local PI or Co-PI). * Patients need to be on stable medical treatment, defined as no new heart failure drug started over the preceding 2 weeks and no major drug dose modification (apart minor adaptations, like weight adaptations, rounding or formulation changes) during the 2 weeks prior to enrolment. * Adolescents, respectively parents or caregivers of children, capable of giving informed consent.
Exclusion criteria
* Inability to understand and go through the informed consent procedure. * Inability to receive medications per os or through a nasogastric tube. * Patients on either Insulin or Metformin will be excluded from participation. This implies the exclusion of patients with Diabetes mellitus (either type 1 or type 2 or other rare forms) necessitating either insulin or metformin. * Type 1 Diabetes mellitus or any underlying metabolic disease associated with hypoglycaemias. * Body weight \<13kg. * Current smokers (defined as \>1 cigarette/week). * Use of any other nicotine-delivering product (e.g. nicotine patches). * Any known illicit drug abuse. * Active chronic HBV, HCV or HIV. * Any major surgery within 4 weeks of first dose administration. * Blood transfusion recipient within 4 weeks of dose administration. * eGFR =\<45mL/min/1.73m2 (simplified Schwartz formula). * K+ \>6.5mmol/L. * Blood glucose \<4mmol/L. * There are no blood pressure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics 1: Dapagliflozin, respectively Empagliflozin half-life | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | This will be derived by pharmacokinetic analysis and modeling, basing on Dapagliflozin, respectively Empagliflozin, concentrations at the different time-points (5-6 samples \[according to weight\] at Visit 1, 1 opportunistic sample at Visits 2 and 3 for Drug A; 5-6 samples \[according to weight\] at Visit 3 and 1 opportunistic sample at Visit 4 for Drug B; the timing of the samples will be optimized with modeling & simulation techniques). |
| Pharmacokinetics 3: Dapagliflozin, respectively Empagliflozin AUC | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | This will be derived by pharmacokinetic analysis and modeling, basing on Dapagliflozin, respectively Empagliflozin, concentrations at the different time-points (5-6 samples \[according to weight\] at Visit 1, 1 opportunistic sample at Visits 2 and 3 for Drug A; 5-6 samples \[according to weight\] at Visit 3 and 1 opportunistic sample at Visit 4 for Drug B; the timing of the samples will be optimized with modeling & simulation techniques). |
| Pharmacokinetics 2: Dapagliflozin, respectively Empagliflozin Volume of distribution | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | This will be derived by pharmacokinetic analysis and modeling, basing on Dapagliflozin, respectively Empagliflozin, concentrations at the different time-points (5-6 samples \[according to weight\] at Visit 1, 1 opportunistic sample at Visits 2 and 3 for Drug A; 5-6 samples \[according to weight\] at Visit 3 and 1 opportunistic sample at Visit 4 for Drug B; the timing of the samples will be optimized with modeling & simulation techniques). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ease-of-swallow | Visit 1, Visit 3 (Visit 1 = day 1, Visit 3 = week 3 to 5 after study start) | Ease of swallow will be assessed by means of facial hedonic scales, according to our standard procedure, at Visit 1 (Drug A), and Visit 3 (Drug B). (Scale 1 to 4, 1 being the worse and 4 the best score: very difficult - difficult - possible - easy to swallow.) |
| Efficacy and efficacy markers (exploratory) 1 - Heart failure severity class | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | Symptoms, clinical signs, NYHA (if \>8 years of age) / Ross (if \<8 years of age) class assignment. NYHA and Ross heart failure classes share the same scale of I (no limitation of physical activity) to IV (symptoms at rest). Analysis will be performed at Visit 1, Visit 3 and Visit 4. Outcome: change between Visit 1 and Visit 4. |
| Efficacy and efficacy markers (exploratory) 2 - NT-proBNP level | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | Analysis will be performed at Visits 1, 3 and 4. Outcome: change between Visit 1 and Visit 4. |
| Efficacy and efficacy markers (exploratory) 3 - Echocardiography 1: Left-ventricular end-diastolic diameter (LVEDd) | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | LVEDd (mm) will be measured at Visits 1, 3 and 4. Outcome: change between Visit 1 and Visit 4. |
| Efficacy and efficacy markers (exploratory) 4 - Echocardiography 2: Left-ventricular end-systolic diameter (LVESd) | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | LVESd (mm) will be measured at Visits 1, 3 and 4. Outcome: change between Visit 1 and Visit 4. |
| Efficacy and efficacy markers (exploratory) 5 - Echocardiography 3: Fractional shortening (FS) | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | FS (%) will be measured at Visits 1, 3 and 4. Outcome: change between Visit 1 and Visit 4. |
| Efficacy and efficacy markers (exploratory) 6 - Echocardiography 4: Left ventricular ejection fraction (LV-EF) | Visits 1, 3 and 4 (Visit 1 = day 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | LV-EF (%) will be measured at Visits 1, 3 and 4. Outcome: change between Visit 1 and Visit 4. |
| Safety 1 - eGFR | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | Creatinine (respectively Cystatin C in DMD participants) will be collected in order to calculate eGFR (bedside Schwartz formula, respectively Filler equation). |
| Safety 2 - Occurrence of hypoglycemia | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | Blood glucose will be checked three times at Visit 1 and Visit 3 (baseline, at the time of 2nd PK sampling, which will be individualized but will be at approximately 2-3h post-intake, and before discharge at 8h post-intake), as well as once at Visits 2 and 4 (together with PK sampling). Outcome measure: number of patients experiencing hypoglycemia. |
| Safety 3 - Occurrence of ketoacidosis | Visits 1-4 (Visit 1 = day 1, Visit 2 = week 1, Visit 3 = week 3 to 5, Visit 4 = week 4 to 6 after study start) | The outcome is presence (or absence) of ketoacidosis. This will be assessed at Visits 1, 2, 3, and 4. Outcome measure: number of patients experiencing ketoacidosis. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Efficacy markers (exploratory), Mechanistic insights - 5: haemoglobin (g/L) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on haemoglobin, haemoglobin will be assessed (outcome: change between Visit 1 and Visit 4). |
| Efficacy markers (exploratory), Mechanistic insights - 6: uric acid (mmol/L) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on uric acid homeostasis, uric acid will be assessed (outcome: change between Visit 1 and Visit 4). |
| Efficacy markers (exploratory), Mechanistic insights - 4: b-hydroxybutyrate (mmol/L) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on metabolism shift, b-hydroxybutyrate will be assessed (outcome: change between Visit 1 and Visit 4). |
| Efficacy markers (exploratory), Mechanistic insights - 3: blood pressure (SBP/DBP, mmHg) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on sympathetic activation, blood pressure (SBP and DBP, in mmHg) will be assessed (outcome: change between Visit 1 and Visit 4). |
| Efficacy markers (exploratory), Mechanistic insights - 2: heart rate (bpm) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on sympathetic activation, heart rate (in bpm) will be assessed (outcome: change between Visit 1 and Visit 4). |
| Efficacy markers (exploratory), Mechanistic insights - 1: body weight (kg) | Visit 1, Visit 4 (Visit 1 = day 1, Visit 4 = week 4 to 6 after study start) | To explore the effect of SGLT2 inhibitors on fluid status, body weight will be assessed (outcome: change between Visit 1 and Visit 4). |
Countries
Switzerland, United Kingdom
Contacts
Primary ContactSebastiano A.G. Lava, MD MSc
Backup ContactCraig Laurence, MD
Outcome results
None listed